NEW YORK (GenomeWeb News) – Plant genomics firm Evogene plans to go public in the US with an initial public offering of up to $60 million.

The company, which trades on the Tel Aviv Stock Exchange, filed to go public with the US Securities and Exchange Commission late on Monday, saying it plans to list on the New York Stock Exchange under ticker symbol "EVGN."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In a series of articles, medical journals debate the necessity of conflict-of-interest policies.

Irwin Rose, who won the 2004 Nobel Prize in Chemistry for his work on ubiquitin-mediated protein degradation, has died.

In Cell this week: biobank of colorectal cancer organoids, ancient wolf genome analysis, and more.

With cloud computing becoming more attractive to researchers, Nature News offers some tips on how to get going.